new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Glaxo Group Limited
Glaxo Group Limited A Corporation

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Glaxo Group Limited patents


      
Recent patent applications related to Glaxo Group Limited. Glaxo Group Limited is listed as an Agent/Assignee. Note: Glaxo Group Limited may have other listings under different names/spellings. We're not affiliated with Glaxo Group Limited, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Glaxo Group Limited-related inventors




Search recent Press Releases: Glaxo Group Limited-related press releases
Count Application # Date Glaxo Group Limited patents (updated weekly) - BOOKMARK this page
12016016678406/16/16 Device housing for an aerosol container
22016015978606/09/16 Chemical process
32016015158806/02/16 Pharmaceutical metered dose inhaler and methods relating thereto
42016009584004/07/16 Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
52016007441303/17/16 Substituted diketopiperazines and their use as oxytocin antagonists
62016007568503/17/16 Novel crystal form
72016007577403/17/16 Anti-serum albumin binding variants
82016006982603/10/16 Sample plate for an x-ray powder diffraction apparatus
92016003044202/04/16 Novel compounds
102016002419701/28/16 Antibodies against amyloid-beta peptide
112016000971601/14/16 2 - (azaindol-2-yl) benz imidazoles as pad4 inhibitors
122016001011101/14/16 Production methods
132016000222001/07/16 Muscarinic acetylcholine receptor antagonists
142015036829212/24/15 Method of producing a protein
152015036103912/17/15 Sulfonamide compounds and their use in the modulation retinoid-related orphan receptor
162015036117612/17/15 Ligands that bind tgf-beta receptor ii
172015034289712/03/15 Polypeptide loaded poca nanoparticles for oral administration
182015034315912/03/15 Inhaler device
192015032804411/19/15 Guide device for a liquid dispenser
202015032822611/19/15 Novel compounds
212015031384111/05/15 Combination of umeclidinium, fluticasone propionate and salmeterol xinafoate for use in the treatment of inflammatory or respiratory tract diseases
222015030605810/29/15 Composition comprising a single variable domain and camostat mesylate (cm)
232015030748510/29/15 3 -amino- pyrazole derivatives useful against tuberculosis
242015029761410/22/15 Combination of levocabastine and fluticasone furoate for the treatment of inflammatory and/or allergic conditions
252015029912110/22/15 Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases
262015029917710/22/15 Novel polymorphs and salts
272015029922310/22/15 2-substituted cephem compounds
282015028445410/08/15 Anti-serum albumin binding variants
292015026553909/24/15 Formulation for retinoid-containing soft gelatin capsules
302015025114809/10/15 Container system for mixing and dispensing a drink
312015023847008/27/15 Muscarinic acetylcholine receptor antagonists
322015023242308/20/15 Chemical process
332015020917807/30/15 Liquid droplet dispenser
342015020931907/30/15 Compositions comprising an antibody and camostat mesylate (cm)
352015021076707/30/15 Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
362015021201607/30/15 Sample plate for an x-ray powder diffraction apparatus
372015020217207/23/15 Novel use
382015020385107/23/15 Inhibitors of bromodomain-containing protein pcaf for the treatment of autoimmune and inflammatory diseases or for the treatment of cancer
392015019756507/16/15 Novel ligand
402015018242707/02/15 Silica abrasive-free dentifrice composition
412015016650806/18/15 Novel compounds
422015015764006/11/15 Novel compounds
432015010817804/23/15 Re-sealable container
442015010538704/16/15 Substituted diketopiperazines and their use as oxytocin antagonists
452015009975604/09/15 Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2
462015009341404/02/15 Modified antigens
472015009344004/02/15 Aggregate nanoparticulate medicament formulations, manufacture and use thereof
482015008034303/19/15 Benzofuran compounds for the treatment of hepatitis c virus infections
492015008036903/19/15 Novel compounds
502015006420103/05/15 Antigen binding proteins to oncostatin m (osm)
512015006550703/05/15 Novel compounds
522015004537502/12/15 Novel compounds
532015000410501/01/15 Novel composition
542014037848712/25/14 Tricyclic compounds, preparation methods, and their uses
552014037126412/18/14 Muscarinic acetylcholine receptor antagonists
562014033508311/13/14 Methods of treatment and prevention of eye diseases
572014031197710/23/14 Use of organic solvent nanofiltration and liquid-liquid chromatography for the recovery of pharmaceutical products
582014028813309/25/14 3 -amino- pyrazole derivatives useful against tuberculosis
592014022725908/14/14 Modified proteins and peptides
602014022726408/14/14 Drug fusions and conjugates with extended half life
612014020560407/24/14 Antigen binding constructs
622014020566107/24/14 Formulation for retinoid-containing soft gelatin capsules
632014020021807/17/14 Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
642014019340707/10/14 Drug fusions and conjugates
652014018775007/03/14 Methods for selecting protease resistant polypeptides
662014017971506/26/14 2,3-dihydroimidazo[1 ,2-c] pyrimidin-5(1 h)-one compounds use as lp-pla2 inhibitors
672014015870406/12/14 Medicament dispenser
682014014099605/22/14 Anti-serum albumin biding variable domains
692014011643405/01/14 Dry powder inhaler compositions
702014011292904/24/14 Tumour necrosis factor receptor 1 antagonists
712014011388804/24/14 Novel combination of therapeutic agents
722014011392204/24/14 Compounds
732014010589404/17/14 Humanized anti-il-18 antibodies
742014010591504/17/14 Bcma (cd269/tnfrsf17) - binding proteins
752014007631403/20/14 Manifold for use in medicament dispenser
762014008086303/20/14 Muscarinic acetylcholine receptor antagonists
772014005690002/27/14 Method for inhibiting binding to b-cell receptor
782014005810502/27/14 Substituted diketopiperazines and their use as oxytocin antagonists
792014005071902/20/14 Antibodies
802014005172002/20/14 N-cyclobutyl - imidazopyridine - methylamine as trpv1 antagonists
812014003898902/06/14 Tetrahydropyrazolo [1,5-a] pyrimidine as anti-tuberculosis compounds
822014002359601/23/14 Novel composition
832014002455801/23/14 Method of treatment
842014000517701/02/14 Pyridinyl- and pyrazinyl-methyloxy-aryl derivatives useful as inhibitors of spleen tyrosine kinase (syk)
852014000518801/02/14 Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
862013034546512/26/13 Process for the preparation of retigabine
872013033698912/19/13 Methods of identifying a patient population
882013031590111/28/13 Novel uses
892013031704111/28/13 Compounds
902013031028111/21/13 Novel antigen binding proteins
912013030233511/14/13 Ligands that bind tgf-beta receptor ii
922013026771710/10/13 Process for the preparation of atovaquone
932013026118510/03/13 Benzamide derivatives as ep4 receptor agonists
942013025172409/26/13 Antigen binding proteins to oncostatin m (osm)
952013025318809/26/13 Novel compounds
962013023750109/12/13 Benzofuran compounds for the treatment of hepatitis c virus infections
972013022420408/29/13 Method of treatment based on atad2 inhibitors
982013021315408/22/13 Method of determining cleanliness
992013021339408/22/13 Dispensing device
1002013021765808/22/13 Pyrazole compounds acting against allergic, inflammatory and immune disorders
1012013021089208/15/13 Method of treatment
1022013020370508/08/13 Pyrazole compounds acting against allergic, immune and inflammatory conditions
1032013020380208/08/13 3 -amino- pyrazole derivatives useful against tuberculosis
1042013019641208/01/13 Magi polynucleotides, polypetides, and antibodies
1052013018925507/25/13 Fusions and conjugates of insulinotropic agents
1062013013133805/23/13 Substituted diketopiperazines as oxytocin antagonists
1072013011813205/16/13 Machine and pharmaceutical and pharmaceutical-like product assembly
1082013010969005/02/13 Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
1092013010278304/25/13 Substituted diketopiperazines and their use as oxytocin antagonists
1102013007819803/28/13 Novel use
1112013005337502/28/13 Amino-quinolines as kinase inhibitors
1122013003947002/14/13 Sample plate for an x-ray powder diffraction apparatus
1132013004098402/14/13 7-(lh-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors
1142013003001201/31/13 Compounds
1152013003001501/31/13 Muscarinic acetylcholine receptor antagonists
1162013002354101/24/13 Voltage-gated sodium channel blockers
1172013001249101/10/13 Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
1182012031620212/13/12 Compounds which have activity at m1 receptor and their uses in medicine
1192012030972512/06/12 Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
1202012030978912/06/12 Compounds which have activity at m1 receptor and their uses in medicine
1212012028854411/15/12 Novel retigabine composition
1222012027727911/01/12 Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions
1232012025146810/04/12 Compositions comprising alginates with high guluronic acid/mannuronic acid ratio for use in the treatment of dentine hypersensitivity
1242012024074209/27/12 Novel device
1252012024517109/27/12 Benzpyrazole derivatives as inhibitors of pi3 kinases
1262012023855909/20/12 Novel compounds
1272012023857109/20/12 Indazole derivatives as pi 3-kinase
1282012023206109/13/12 Novel compounds
1292012020774908/16/12 Dosing regimen
1302012020281108/09/12 Novel compounds
1312012015744606/21/12 Medical use
1322012015749106/21/12 Muscarinic acetylcholine receptor antagonists
1332012015749206/21/12 Antibiotic drug
1342012014971106/14/12 Piperidine derivatives used as orexin antagonists
1352012014973106/14/12 New medical use
1362012012868905/24/12 Anti-il-23 immunoglobulins
1372012012977805/24/12 Ligand that bind tgf-beta receptor rii
1382012011464705/10/12 Anti-serum album single variable domains
1392012010013704/26/12 Immunoglobulins
1402012010108304/26/12 S1p1 agonists comprising a bicyclic n-containing ring
1412012010108604/26/12 Thiadiazole derivatives and their use for the treatment of disorders mediated by s1p1 receptors
1422012010112404/26/12 1,2,4-oxadiazol derivatives, their pharmaceutical compositions and their use as sphingosine 1-phosphate 1 receptor agonists
1432012010113404/26/12 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
1442012010113604/26/12 5-membered heteroaryl derivatives used as sphingosine 1- phosphate receptor agonists
1452012006517703/15/12 Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
1462012005896303/08/12 Macrolides with anti-inflammatory activity
1472012004625802/23/12 Novel crystalline pharmaceutical product
1482012004646902/23/12 Process for the preparation of a biphenyl-2-yl carbamic acid ester
1492012003982002/16/12 Antibacterial composition comprising 4-isopropyl-3-methylphenol and zinc ions
1502012004099102/16/12 3-azabicyclo [4.1.0] heptanes used as orexin antagonists
1512012004102702/16/12 Benzimidazoles which have activity at m1 receptor and their uses in medicine
1522012004102802/16/12 Benzimidazoles which have activity at m1 receptor and their uses in medicine
1532012003431202/09/12 4-isopropyl-3-methylphenol for the treatment of inflammation
1542012000632201/12/12 Drug dispenser
1552012000422901/05/12 Substituted diketopiperazines and their use as oxytocin antagonists
1562011031937112/29/11 Pharmaceutical formulations comprising 4-hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
1572011030569212/15/11 Antigen-binding contructs
1582011030569312/15/11 Anitigen-binding constructs
1592011028809811/24/11 Novel compounds
1602011028190911/17/11 Substituted quinoline derivatives as h1 receptor antagonists
1612011027565511/10/11 Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
1622011027566111/10/11 Tricyclic nitrogen compounds used as antibacterials
1632011026973811/03/11 Compounds
1642011026997011/03/11 Phenethanolamine derivatives for treatment of respiratory diseases
1652011026358810/27/11 Tricyclic compounds as glutamate receptor modulators
1662011025375210/20/11 Nozzle for a nasal inhaler
1672011025607410/20/11 Novel use
1682011024547010/06/11 Immunoglobulins
1692011023779209/29/11 Quinoline derivatives and their use as 5-ht6 ligands
1702011019027408/04/11 Salt of, and processes for the preparation of, 1-isopropyl-4-hexahydro-1h-1,4-diazepine
1712011017806307/21/11 Benzpyrazol derivatives as inhibitors of pi3 kinases
1722011016615007/07/11 Anhydrous crystal form of ovrepitant maleate
1732011015087106/23/11 Treatment of an autoimmune disease using il-18 antagonists
1742011015226206/23/11 Novel compounds
1752011014282406/16/11 Antibodies against amyloid-beta peptide
1762011014415106/16/11 Novel process, salts, composition and use
1772011013569506/09/11 Oral dosage form for controlled drug release
1782011013042306/02/11 Compounds which have activity at m1 receptor and their uses in medicine
1792011011719005/19/11 Pharmaceutical formulations
1802011011826105/19/11 Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
1812011006164603/17/11 Drug dispenser
1822011006474003/17/11 Antigen binding proteins
1832011006572503/17/11 Triazole amide derivatives for use in therapy
1842011005916703/10/11 Encapsulation of biologically active agents
1852011005997903/10/11 Piperidine/cyclohexane carboxamide derivatives for use as vanilloid receptor modulators
1862011004502702/24/11 Adjuvant
1872011004613702/24/11 Pyrazole derivatives as p2x7 modulators
1882011003452402/10/11 Hemi-fumarate salt of a 1,3,4-thiadiazolyl derivative as modulator of the sphingosine 1-phosphate receptor
1892011002157801/27/11 Compounds which potentiate the ampa receptor and uses thereof in medicine
1902011000939401/13/11 Tricyclic nitrogen compounds and their use as antibacterial agents
1912011000963101/13/11 Phenethanolamine derivatives for treatment of respiratory diseases
1922010032999612/30/10 Novel combination of therapeutic agents
1932010032402212/23/10 Novel compounds
1942010031657912/16/10 Novel use of alkyl phosphate esters
1952010031766612/16/10 Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss
1962010031767212/16/10 Monomaleate monohydrate salt of a 5ht1a receptor antagonist
1972010030808212/09/10 Dispensing device
1982010031170612/09/10 Method of treatment of allergic rhinitis
1992010031173412/09/10 Spiro compounds useful as antagonists of the h1 receptor
2002010030382112/02/10 Immunoglobulins
2012010030510712/02/10 Quinoline derivatives and their use as 5-ht6 ligands
2022010030512712/02/10 Novel compounds
2032010030516612/02/10 Novel compounds
2042010029222411/18/10 Isothiazolidine 1,1-dioxide and tetrahydro-2h-1,2-thiazine 1,1-dioxide derivatives as p2x7 modulators
2052010029229511/18/10 5-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators
2062010028615211/11/10 N-phenyl hydrazides as modulators of the ghrelin receptor
2072010027590911/04/10 Actuator for an inhaler
2082010027385310/28/10 Novel isoindol derivatives as ep4 receptor agonists
2092010026769110/21/10 Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
2102010026773410/21/10 N-[(3,5-dichlorophenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-(1-naphthalenyl)ethanamide as ghrelin receptor modulator
2112010025619910/07/10 Crystalline form of an antimalarial compound
2122010025691910/07/10 Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
2132010023966609/23/10 Process for producing mouldings from (meth) acrylate copolymers by means of injection moulding
2142010022418509/09/10 Actuator for an inhaler
2152010022234909/02/10 Quinoline derivatives used to treat inflammatory and allergic diseases
2162010021679908/26/10 Phthalazine and pyrido[3,4-d]pyridazine compounds as h1 receptor antagonists
2172010021683708/26/10 Glycine transport inhibitors
2182010021067208/19/10 Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
2192010020325608/12/10 Method and the application of powder material to substrates
2202010020424208/12/10 Piperazine derivative having affinity for the histamine h3 receptor
2212010020427308/12/10 Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
2222010019767908/05/10 Compounds
2232010019769908/05/10 I-oxa-3-azaspiro (4.5) decan-2-one and 1-oxa-3, 8-diazaspiro (4.5) decan-2-one derivatives for the treatment of eating disorders
2242010019076407/29/10 Novel compounds
2252010018477007/22/10 Compounds
2262010018499607/22/10 Process of amide formation
2272010017569807/15/10 Capsule
2282010017406507/08/10 Compounds
2292010014809106/17/10 Method and system for rapid phase luminescense spectroscopy analysis
2302010015219506/17/10 Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
2312010014401606/10/10 Apparatus for the disruption of animal cells
2322010014475506/10/10 Novel compounds
2332010014482906/10/10 Novel receptor antagonists and their methods of use
2342010014504006/10/10 Benzazepine derivatives for the treatment of neurological disorders
2352010013727606/03/10 Compounds which potentiate ampa receptor and uses thereof in medicine
2362010013735306/03/10 Tricyclic compounds as antibacterials
2372010013737806/03/10 Pyridine compounds for the treatment of prostaglandin mediated diseases
2382010013742806/03/10 Oxygen containing heterocycles as glycine transporter inhibiting compounds
2392010013058305/27/10 Prolinamide derivatives as modulators of voltage-gated sodium channels
2402010011352105/06/10 Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenylpiperidin-3s-yl-)
2412010011352805/06/10 Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
2422010011379605/06/10 Indole derivatives as s1p1 receptor
2432010010565204/29/10 Purines as cysteine protease inhibitors
2442010010568804/29/10 Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1
2452010010575404/29/10 5-(4phenyl)prolinamide for treatment of epilepsy
2462010008742404/08/10 Tricyclic nitrogen containing heterocycles as antibacterial agents
2472010008750204/08/10 Indazoles used to treat estrogen receptor beta mediated disorders
2482010008766704/08/10 Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
2492010008183004/01/10 Methods of synthesizing n-hydroxysuccinimidyl carbonates



ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Glaxo Group Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxo Group Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###